Subgroup analyses by performance status (PS) in the phase III SQUIRE study: First-line necitumumab (N) plus gemcitabine-cisplatin (GC) vs. GC in squamous non-small cell lung cancer (NSCLC).
Year: 2015
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: University of Pittsburgh, Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center", Samsung Medical Center, Sungkyunkwan University, German Center for Lung Research, LungenClinic Grosshansdorf, Eli Lilly (Germany), Eli Lilly (United States), The Christie Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2936631831